Pharmasset receives new US patent for HCV drug
The new patent entitled, ‘Nucleoside Phosphoramidate Prodrugs,’ is related to the composition and matter of PSI-7977 and its diastereomeric mixture indicated for the treatment of hepatitis C virus
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.